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L E T T E R  T O  T H E  E D I T O R
Genetic predisposition to allergic diseases is inversely 
associated with risk of COVID-19
To the Editor,
The host immune response is integral to determining susceptibility to 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec-
tion and severity of consequent coronavirus disease 2019 (COVID-
19).1 Allergic diseases such as allergic rhinitis (hay fever), atopic 
dermatitis (eczema) and asthma tend to cluster together in individuals, 
partly because of shared genetic factors that navigate the immune sys-
tem.2 However, it is not yet known whether genetic predisposition to 
allergic disease also relates to COVID-19 susceptibility. Understanding 
this relationship may provide mechanistic insight towards uncovering 
preventative and therapeutic strategies for COVID-19. To this end, we 
performed a Mendelian randomization analysis investigating how ge-
netic predictors of allergic disease relate to COVID-19 susceptibility.
As genetic instruments for the primary analysis, we considered 
136 uncorrelated (r2 < 0.02) single nucleotide polymorphisms asso-
ciated with a broad allergic disease phenotype (presence of at least 
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F I G U R E  1  Associations of genetic predisposition to any allergic disease with COVID-19 with different Mendelian randomization 
statistical analysis methods with different assumptions. The I2 value for heterogeneity between individual genetic variants was ≤27%. The 
p value for the intercept in the MR-Egger analyses was >0.16 in all analyses. No outlier SNP was detected in the MR-PRESSO analysis. CI: 
confidence interval; Con-Mix, contamination mixture; IVW, inverse-variance weighted; MR, Mendelian randomization; OR: odds ratio; 
PRESSO, Pleiotropy RESidual Sum and Outlier
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one allergic disease, including allergic rhinitis, atopic dermatitis and 
asthma) at p < 3 × 10−8 in a meta-analysis of 13 genome-wide as-
sociation studies with a total of 180 129 cases and 180 709 con-
trols (without the three allergic diseases), all of European descent.2 
Information on allergic disease was self-reported. The number of 
cases with each allergic disease is shown in Table S1. The association 
estimates were adjusted for age, sex and genetic principal compo-
nents of ancestry.2 In secondary analyses, we separately considered 
single nucleotide polymorphisms associated with each allergic dis-
ease (Appendix S1).
Genetic association estimates for COVID-19 susceptibility 
were obtained from the COVID-19 Host Genetics Initiative ge-
nome-wide association meta-analyses (round 4, release October 
20, 2020).3 To minimize population stratification bias, we re-
stricted the analyses to individuals of European ancestry. The 
publicly available datasets comprising European-descent individ-
uals included 14 134 cases with laboratory-confirmed COVID-19 
infection (RNA and/or serology-based) or physician confirmed 
COVID-19 vs. 1 284 876 population controls (everyone that is 
not a case) and 6406 cases of hospitalized laboratory-confirmed 
COVID-19 infection versus 902 088 population controls. Of the 
136 single nucleotide polymorphisms associated with any allergic 
disease, 130 were available in the COVID-19 outcome datasets. 
Details of the single nucleotide polymorphisms and their associa-
tions with COVID-19 are shown in Table S2.
We conducted two-sample summary-level Mendelian ran-
domization analyses using the random-effects inverse-variance 
weighted method (primary analysis) and several statistical sensitivity 
analysis methods that make different assumptions.4 Analyses were 
conducted in Stata/SE (version 14.2) and R (version 3.4.3) using sum-
mary-level data only. Ethical approval and participant consent had 
previously been obtained.
Genetic predisposition to any allergic disease was associated 
with reduced susceptibility to COVID-19 but not clearly with risk 
of being hospitalized with COVID-19 (Figure 1). Similar results were 
observed in statistical sensitivity analyses, although with wider con-
fidence intervals that were likely attributable to lower statistical 
power (Figure 1). The associations of each single nucleotide poly-
morphism with allergic disease and COVID-19 susceptibility are dis-
played in Figure S1. Secondary analyses based on genetic variants 
associated with different allergic diseases did not reveal associations 
with any particular allergic disease specifically, although the mag-
nitude of the inverse association was most pronounced for allergic 
rhinitis albeit with broad confidence intervals (Figure S2).
Our results provide evidence to support that the genetic factors 
underlying predisposition to allergic disease are protective against 
COVID-19. The pathophysiological process underlying COVID-19 
involves an exaggerated host immune response.5 Previous work has 
highlighted genetic associations between obesity and smoking with 
both allergic disease and severe COVID-19,2,6 supporting immune 
dysregulation as a common underlying mechanism. Further work is 
required to unravel the specific pathways linking susceptibility to 
allergic disease with risk of COVID-19, for the purpose of identifying 
opportunities for clinical intervention.
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